Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

GLPG1690 is a novel autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis (IPF). We report phase 1 studies investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG1690 in healthy subjects. We performed a first‐in‐human randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Aar, Ellen, Desrivot, Julie, Dupont, Sonia, Heckmann, Bertrand, Fieuw, Ann, Stutvoet, Simone, Fagard, Liesbeth, Van de Wal, Karen, Helmer, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767429/
https://www.ncbi.nlm.nih.gov/pubmed/31012984
http://dx.doi.org/10.1002/jcph.1424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767429/
https://www.ncbi.nlm.nih.gov/pubmed/31012984
http://dx.doi.org/10.1002/jcph.1424

Ejemplares similares